Grant: Idea to Innovation
University of Toronto
$125,000.00
Digital microfluidics for multiplexed cell-based screening
EF 2009-10
Résumé
We propose to develop a unique high-throughput screening tool that will be useful for early-stage
pharmaceutical discovery. The new tool will rely on digital microfluidics (DMF), a technology in which
droplets are manipulated on an open platform without any moving parts, valves or tubes. DMF enables fluid
handling operations such as translating, merging, mixing and splitting of droplets, which can be utilized to
perform large, parallel-scale bioassays. We propose to build a prototype instrument in which DMF-driven
arrays of droplets containing mammalian cells are addressed with compounds from chemical libraries, and the
potential drugs evaluated on the basis of observed changes in cells. The new method will facilitate
100-1000-fold reduction in reagent use, and will be compatible with standard laboratory instruments and
infrastructure. We will demonstrate the utility of the new technique by implementing a pilot screen to discover
"hits" with (potential) anti-cancer activity.
This proposal is built on our preliminary work, in which we developed the first cell-based assays in droplets on
a DMF platform. Working with The Innovation Group at the University of Toronto, we recently filed several
patents describing these (and other) innovations related to digital microfluidics. This work has attracted the
attention of several prospective industrial partners including Tecan Group Ltd. (an international leader in the
liquid handling and multiplexed analysis markets) and the pharmaceutical giant, Eli Lilly. We hope that
NSERC will fund this proposal, which will support the development of a new Canadian-grown technology that
has the potential to revolutionize high-throughput screening and drug discovery.
Programme
Idea to Innovation
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
379832-2008
Name nom
Wheeler, Aaron
Department département
Chemistry
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2009
Competition year année de concours
2008
Award amount
125000
Program id
I2IPJ
Program nane en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3504
Research subject group en
Analytical chemistry
Research subject group fr
Chimie analytique
Research subject en
Bioanalytical chemistry
Research subject fr
Chimie bioanalytique
Partie
1
Nb partie
1
Application title
Digital microfluidics for multiplexed cell-based screening
Keyword
NA
Application summary
We propose to develop a unique high-throughput screening tool that will be useful for early-stage
pharmaceutical discovery. The new tool will rely on digital microfluidics (DMF), a technology in which
droplets are manipulated on an open platform without any moving parts, valves or tubes. DMF enables fluid
handling operations such as translating, merging, mixing and splitting of droplets, which can be utilized to
perform large, parallel-scale bioassays. We propose to build a prototype instrument in which DMF-driven
arrays of droplets containing mammalian cells are addressed with compounds from chemical libraries, and the
potential drugs evaluated on the basis of observed changes in cells. The new method will facilitate
100-1000-fold reduction in reagent use, and will be compatible with standard laboratory instruments and
infrastructure. We will demonstrate the utility of the new technique by implementing a pilot screen to discover
"hits" with (potential) anti-cancer activity.
This proposal is built on our preliminary work, in which we developed the first cell-based assays in droplets on
a DMF platform. Working with The Innovation Group at the University of Toronto, we recently filed several
patents describing these (and other) innovations related to digital microfluidics. This work has attracted the
attention of several prospective industrial partners including Tecan Group Ltd. (an international leader in the
liquid handling and multiplexed analysis markets) and the pharmaceutical giant, Eli Lilly. We hope that
NSERC will fund this proposal, which will support the development of a new Canadian-grown technology that
has the potential to revolutionize high-throughput screening and drug discovery.